Catalyst Wire Dossier Catalyst Wire Dossier

Galcanezumab-gnlm

galcanezumab-gnlm · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Galcanezumab-gnlm, covering 2025-03-30 to 2025-03-30. Get the full timeline:

Most recent: Clinical Trial Update: The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches [Phase 4]

See pricing